文献速递临床试验与 GCP

早产儿动脉导管未闭的期待管理 vs 药物治疗:PDA随机临床试验

Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

这项随机临床试验纳入胎龄22至28周、符合方案定义动脉导管未闭(PDA)的早产儿,比较期待管理与积极治疗(对乙酰氨基酚、布洛芬或吲哚美辛)对死亡或支气管肺发育不良(BPD)的影响。结果显示两组死亡或BPD发生率无显著差异,但期待管理组生存率显著更高。

要点

  • 期待管理组与积极治疗组的死亡或BPD发生率分别为80.9%与79.6%,无显著差异。
  • 期待管理组36周矫正胎龄前死亡发生率4.1%,低于积极治疗组的9.6%。
  • 试验因期待管理组生存率更高,在50%期中分析后因无效性和安全性提前终止。

核心结论

  • 在符合方案定义的PDA的极早产儿中,期待管理组与积极治疗组的死亡或BPD发生率无显著差异,期待管理组生存率显著更高。

研究设计与样本

  • 随机临床试验,纳入胎龄22至28周、在筛查时48小时至21日龄之间诊断为方案定义PDA的早产儿,2018年12月至2024年12月在33家医院开展,最终随访日期为2025年6月。
  • 共482例婴儿随机分组:期待管理组242例,积极治疗组240例;积极治疗使用对乙酰氨基酚、布洛芬或吲哚美辛关闭PDA。
  • 婴儿中位胎龄25周(IQR 24至27周),中位出生体重760 g(IQR 620至935 g)。

主要发现

  • 主要结局死亡或BPD发生率:期待管理组80.9%(195/241) vs 积极治疗组79.6%(191/240),校正风险差1.2%(95%CI -5.7%至8.1%),P=0.73。
  • 36周矫正胎龄前死亡发生率:期待管理组4.1%(10/241) vs 积极治疗组9.6%(23/240),校正风险差-5.6%(95%CI -10.1%至-1.2%),P=0.01。
  • 感染导致死亡:期待管理组0.8%(2/241) vs 积极治疗组3.8%(9/240)。
  • 试验在主要结局50%期中分析后因无效性和安全性提前终止,原因是期待管理组生存率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The management of patent ductus arteriosus (PDA) in preterm infants is controversial. OBJECTIVE: To determine whether expectant management compared with active treatment of a protocol-defined PDA in preterm infants decreases the incidence of death or bronchopulmonary dysplasia (BPD). DESIGN, SETTING, AND PARTICIPANTS: A randomized clinical trial including infants born at 22 to 28 weeks' gestation and diagnosed with a protocol-defined PDA between the age of 48 hours and 21 days at screening. The trial was conducted from December 2018 to December 2024 at 33 hospitals within the National Institute of Child Health and Human Development Neonatal Research Network. The final date of follow-up was June 2025. INTERVENTIONS: Infants with PDA were randomized to expectant management (n = 242) or active treatment (n = 240; acetaminophen, ibuprofen, or indomethacin) to close the PDA. MAIN OUTCOMES AND MEASURES: The primary outcome was death or BPD at 36 weeks' postmenstrual age. The secondary outcomes included the components of the primary outcome and other morbidities of prematurity. RESULTS: A total of 482 infants were randomized (median gestational age, 25 weeks [IQR, 24 to 27 weeks]; median birth weight, 760 g [IQR, 620 to 935 g]). The trial was stopped for futility and safety after the 50% interim analysis for the primary outcome due to higher survival in the expectant management group. The incidence of death or BPD was 80.9% (195/241) of infants in the expectant management group vs 79.6% (191/240) of infants in the active treatment group (adjusted risk difference, 1.2% [95% CI, -5.7% to 8.1%]; P = .73). The incidence of death before 36 weeks' postmenstrual age was 4.1% (10/241) of infants in the expectant management group vs 9.6% (23/240) of infants in the active treatment group (adjusted risk difference, -5.6% [95% CI, -10.1% to -1.2%]; P = .01). Infections resulting in death occurred in 0.8% (2/241) of infants in the expectant management group vs 3.8% (9/240) of infants in the active treatment group. CONCLUSIONS AND RELEVANCE: In extremely preterm infants with a protocol-defined PDA, death or BPD did not differ between the expectant management group and the active treatment group. Survival was substantially higher with expectant management. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03456336.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Laughon MM, Thomas SM, Watterberg KL, et al. Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants: The PDA Randomized Clinical Trial. JAMA. 2026. PMID: 41364689. doi:10.1001/jama.2025.23330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。